New Delhi, Feb 7 (PTI) Drug firm Lupin on Wednesday reported a four-fold jump in its consolidated net profit at Rs 613 crore for the third quarter ended December 2023, led by robust sales growth across geographies.

The company had reported a net profit of Rs 153 crore in the October-December quarter of the last fiscal.

Also Read | CTET Exam 2024: Provisional Answer Key and OMR Answer Sheets of Central Teacher Eligibility Test January Examination Released at ctet.nic.in, Know Steps To Check.

Its revenue from operations rose to Rs 5,197 crore in the period under review from Rs 4,322 crore in the year-ago period, Lupin said in a statement.

"We delivered our highest quarterly sales to date and crossed the Rs 5,000 crore mark for the first time, driven by strong growth across geographies," Lupin Ltd Managing Director Nilesh Gupta said.

Also Read | Union Bank of India Recruitment 2024: Applications Invited for 606 Specialist Officer Posts Till February 23, Apply Online at unionbankofindia.co.in.

The US market continues to do well, driven by demand for both in-line products and new launches, and the India business continues to grow ahead of the market with strong growth across key therapies, he added.

"This positive growth momentum coupled with cost optimisation measures and operating leverage has helped us deliver solid performance," Gupta stated.

(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)